Scientific Co-Founder

GO Therapeutics - Henrik ClausenHenrik Clausen DDS, D.Sc. is director of the center for glycobiology at the University of Copenhagen and a leading figure in the world of glycobiology and carbohydrate chemistry.

Over the past 20 years, his research interest has been focused on chemistry, biosynthesis, and the genetics of complex carbohydrates as well as the biological roles these play in cancer biology, infectious diseases and as alloantigens. Dr. Clausen has made major contributions to the understanding of the chemistry of the major blood group ABO system and has elucidated the enzymes and genes responsible for the ABO system.

In the last10 years Dr. Clausen’s research has primarily focused on the biosynthesis and genetic regulation of the carbohydrates on mucins, and his laboratory has identified and patented a wide array of the essential enzymes, genes and methods required for the glycosylation of mucins.

His laboratory has in particular been focused on the unique class of polypeptide GalNAc-transferase enzymes that initiates mucin glycosylation, and the laboratory has played a world-leading role in this field for many years. The laboratory has published numerous papers in the field and is funded by national as well as prestigious international funding from NIH, EU Biotech, and the Human Frontier Science Program.